A Long-Term, Open-Label Study Of CP-690,550 To Confirm The Safety Following Long Term Administration Of CP-690,550 In The Treatment Of Rheumatoid Arthritis.

Trial Profile

A Long-Term, Open-Label Study Of CP-690,550 To Confirm The Safety Following Long Term Administration Of CP-690,550 In The Treatment Of Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Nov 2017 Pooled results of two open-label studies (NCT00413699 and NCT00661661), were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Pooled results of two open-label studies (NCT00413699 and NCT00661661; n=4967) assessing long-term safety and efficacy of Tofacitinib over 9 years, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results of a post hoc analysis from pooled data of this, two Phase II studies (NCT00603512 and NCT00687193), and Phase III study (ORAL Scan; NCT00847613) presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top